文献速递前列腺癌

≤50岁前列腺癌患者的肿瘤特征、治疗与肿瘤学结局:基于人群研究

Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-01-16

基于SEER数据库2004至2013年407,599例前列腺腺癌患者,其中18,387例(4.5%)年龄≤50岁。年轻患者肿瘤特征更有利(Gleason评分更低、中位PSA更低、诊断时转移率更低),但2004至2013年新发转移性前列腺癌比例从2%升至3.2%(p=0.004)。竞争风险回归显示年轻与年老患者的前列腺癌特异性死亡率无差异。

要点

  • 年轻(≤50岁)前列腺癌患者诊断时Gleason评分更低、中位PSA更低、转移率更低。
  • 2004至2013年年轻患者新发转移性前列腺癌比例从2%升至3.2%(p=0.004)。
  • 竞争风险回归显示年轻与年老患者的前列腺癌特异性死亡率无差异。

核心结论

  • 年轻前列腺癌患者诊断时疾病特征更有利,接受根治性前列腺切除术或近距离放疗更少,更多接受无局部治疗。
  • 年轻与年老患者的前列腺癌特异性死亡率无差异。
  • 近期更多年轻患者诊断时即为转移期,这一趋势令人担忧。

研究设计与样本

  • 基于SEER数据库2004至2013年407,599例原发性前列腺腺癌患者的基于人群研究。
  • 其中18,387例(4.5%)年龄≤50岁。
  • 采用时间趋势、累积发病率和竞争风险回归分析比较年轻与年老患者的差异。
  • 多变量分析调整了诊断年份、种族、婚姻状况、Gleason评分、临床肿瘤分期和淋巴结状态。

主要发现

  • 年轻患者较年老患者Gleason评分更低、中位PSA更低、诊断时转移率更低。
  • 随时间推移,无局部治疗率增加,根治性前列腺切除术和近距离放疗率下降,外照射放疗率保持不变。
  • 年轻患者新发转移性前列腺癌比例从2004年2%升至2013年3.2%(p=0.004)。
  • 竞争风险回归模型显示,在所有局部治疗类型中,年轻与年老患者的前列腺癌特异性死亡率无差异。

临床怎么用

  • 年轻前列腺癌患者诊断时疾病特征更有利,但需关注新发转移比例上升的趋势。
  • 年轻与年老患者的前列腺癌特异性死亡率无差异,局部治疗选择需综合评估。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To examine clinical characteristics, treatment modalities and oncological outcomes of prostate cancer (PCa) according to young (≤50) vs. old age. METHODS: Of 407,599 men with primary adenocarcinoma of the prostate within the Surveillance, Epidemiology and End Results (SEER)-database (2004 to 2013), 18,387 were aged ≤50 years (4.5%). Time trends, cumulative incidence, and competing risks regression (CRR) analyses tested for differences between young and old patients. Multi-variable analyses were adjusted for year of diagnosis, race, marital status, Gleason Score, clinical tumor stage, and lymph node status. RESULTS: Younger men had more favorable tumor characteristics: lower Gleason Score, lower median PSA, and lower rates of metastases at diagnosis compared to their older counterparts. Over time, no local treatment (NLT) rates increased, radical prostatectomy (RP), and brachytherapy (BT) rates decreased and external beam radiation (EBRT) rates remained unchanged. Moreover, the rate of de novo metastatic prostate cancer increased in young patients from 2% (2004) to 3.2% (2013) (p = 0.004). CRR models showed no difference in prostate cancer-specific mortality (PCSM) between young and old, across all local treatment types. CONCLUSIONS: Young PCa patients have more favorable disease characteristics at presentation, are less frequently treated with RP or BT and more frequently benefit of NLT. PCSM did not differ between young and old patients. However, it is worrisome that recently more young PCa patients are diagnosed at a metastatic stage.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Pompe RS, Smith A, Bandini M, et al. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study. Prostate Cancer Prostatic Dis. 2018. PMID: 29339806. doi:10.1038/s41391-017-0006-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。